{"gene":"AGL","run_date":"2026-06-09T22:02:42","timeline":{"discoveries":[{"year":2007,"finding":"The E3 ubiquitin ligase Malin physically interacts with AGL and promotes its ubiquitination. The disease-causing G1448R variant of AGL is unable to bind glycogen, shows decreased protein stability rescued by proteasomal inhibition, and forms aggresomes upon proteasome impairment, indicating that glycogen binding is required for AGL stability. Stimulation with cAMP-elevating agents increases Malin levels and Malin/AGL complex formation. After glycogen depletion, AGL redistributes from cytoplasm to partial nuclear localization in ~90% of transfected HepG2 cells. Refeeding mice after an overnight fast reduces hepatic AGL levels by 48%, consistent with ubiquitin-mediated degradation.","method":"Co-immunoprecipitation, transfection studies in HepG2 cells, proteasome inhibitor rescue, immunofluorescence localization, in vivo mouse refeeding/fasting experiments, ubiquitination assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP for Malin-AGL interaction, multiple orthogonal methods (ubiquitination assay, proteasome inhibitor rescue, subcellular localization, in vivo mouse experiments), single lab but comprehensive mechanistic dissection","pmids":["17908927"],"is_preprint":false},{"year":1996,"finding":"The human AGL gene encodes a multifunctional enzyme with two distinct catalytic activities: 1,4-alpha-D-glucan:1,4-alpha-D-glucan 4-alpha-D-glycosyltransferase (transferase) and amylo-1,6-glucosidase (glucosidase), both required for glycogen debranching. The gene contains at least two promoter regions conferring tissue-specific isoform expression: promoter 1 (for isoform 1) is active in liver, muscle, and ovary cells, while promoter 2 (for muscle-specific isoforms 2–4) is active only in muscle, as demonstrated by reporter assays.","method":"Gene cloning and structural analysis, reporter (promoter) assays in HepG2, C2C12, and CHO cells, mRNA isoform characterization","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct reporter assays establishing promoter tissue-specificity, single lab, two orthogonal approaches (structural analysis + functional assays)","pmids":["8954797"],"is_preprint":false},{"year":2009,"finding":"A missense mutation p.R1147G in AGL selectively abolishes glucosidase activity while maintaining transferase activity in vitro, demonstrating that these two catalytic activities reside in separable functional domains and that isolated glucosidase deficiency can result from a single missense mutation.","method":"In vitro enzyme activity assays (transferase and glucosidase) on mutant protein from a patient homozygous for p.R1147G, confirmed by clinical diagnosis of isolated glucosidase deficiency","journal":"Journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct in vitro biochemical assay demonstrating dissociable catalytic activities, single case/lab, no independent replication reported","pmids":["19834502"],"is_preprint":false},{"year":2015,"finding":"Loss of AGL in bladder cancer cells drives tumor growth through upregulation of hyaluronic acid synthase 2 (HAS2)-mediated hyaluronic acid (HA) synthesis. siRNA-mediated depletion of HAS2 or pharmacological inhibition of HA synthesis (4-methylumbelliferone) abrogated anchorage-dependent and independent growth, as well as xenograft growth, of AGL-low bladder cancer cells. AGL and HAS2 mRNA expression are inversely correlated in patient datasets.","method":"shRNA/siRNA knockdown, xenograft tumor growth assays, pharmacological inhibition (4MU), transcriptional profiling, clinicopathologic dataset analysis","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal loss-of-function approaches (siRNA, pharmacological inhibitor, xenograft), single lab","pmids":["26490312"],"is_preprint":false},{"year":2016,"finding":"In bladder cancer cells with low AGL expression, HA synthesized by HAS2 signals through receptors CD44 and RHAMM to promote anchorage-dependent and independent growth and suppress apoptosis. Loss of CD44 or RHAMM individually induces apoptosis (evidenced by cleaved Cas3, Cas9, PARP, and TUNEL staining) in AGL-low bladder cancer cell lines, placing CD44 and RHAMM downstream of AGL loss → HAS2 → HA in this tumor growth pathway.","method":"siRNA knockdown of HAS2, CD44, RHAMM; Western blot for apoptosis markers; TUNEL assay; proliferation and soft-agar assays; clinicopathologic analysis of patient datasets","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal knockdown experiments with defined apoptosis and growth readouts, single lab, replicates and extends prior AGL/HAS2 findings","pmids":["27595989"],"is_preprint":false},{"year":2017,"finding":"AAV-mediated restoration of GDE (AGL) expression in liver directly impacts blood glucose levels, while restoration in muscle rescues functional deficits (muscle weakness) without affecting glucose metabolism, establishing tissue-specific roles for GDE: hepatic GDE governs systemic glucose homeostasis and muscle GDE is required for neuromuscular function. Overexpression of the lysosomal enzyme GAA reduced liver glycogen but failed to reverse the overall GSDIII disease phenotype.","method":"AAV vector-mediated gene transfer in Agl knockout mice; tissue-specific expression constructs; functional assays (blood glucose, muscle strength); histological and biochemical quantification of glycogen","journal":"Molecular therapy","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean in vivo rescue with tissue-targeted vectors plus negative control (GAA), multiple functional and biochemical readouts, proof-of-concept replicated across liver and muscle compartments","pmids":["29396266"],"is_preprint":false},{"year":2018,"finding":"Loss of AGL in non-small cell lung cancer (NSCLC) cells promotes anchorage-independent and xenograft tumor growth through upregulation of HAS2-driven HA synthesis, with HA signaling through RHAMM being critical for growth of AGL-low NSCLC cells, extending the AGL → HAS2 → HA → RHAMM tumor-suppressive pathway to a second cancer type.","method":"shRNA knockdown of AGL; siRNA knockdown of HAS2 and RHAMM; pharmacological inhibition of HA synthesis (4MU); soft-agar and xenograft growth assays; patient dataset analysis","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal loss-of-function approaches in a second tumor type, single lab, consistent with prior bladder cancer findings","pmids":["29682180"],"is_preprint":false},{"year":2019,"finding":"Germline Agl knockout mice (with urothelium-specific conditional knockout also generated) show increased bladder cancer incidence upon carcinogen (BBN) treatment compared to wild-type, establishing a direct in vivo tumor-suppressive role for AGL in the urothelium. RNA sequencing of tumors from Agl−/− mice identified 19 differentially expressed genes, enabling derivation of an 'Agl Loss' gene signature.","method":"Germline Agl knockout mouse generation; urothelium-specific conditional knockout (Uroplakin II-Cre); BBN carcinogen treatment; histopathological assessment of bladder cancer incidence; RNA sequencing","journal":"Carcinogenesis","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo germline and conditional knockout with carcinogen challenge, two independent mouse models converging on same phenotype, single lab","pmids":["30403777"],"is_preprint":false},{"year":2024,"finding":"An N-terminal-truncated AGL mutant (ΔNter2-GDE) retains full enzymatic efficacy in vivo, demonstrating that the N-terminal region of GDE is dispensable for glycogen debranching function. rAAV vectors expressing this mini-GDE significantly reduced glycogen accumulation in heart and muscle of Agl−/− mice and corrected histological and functional deficits (including normalization of muscle strength) in both mouse and rat Agl knockout models, and also corrected glycogen accumulation in a human skeletal muscle cellular model of GSDIII.","method":"Molecular modeling and truncation mutagenesis; rAAV-mediated in vivo gene transfer in Agl−/− mice and rats; glycogen quantification; histological analysis; muscle strength testing; in vitro human skeletal muscle cell model correction","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1 / Strong — structure-guided mutagenesis combined with in vivo and in vitro functional rescue in multiple models (mouse, rat, human cells), multiple orthogonal readouts","pmids":["38015640"],"is_preprint":false},{"year":2014,"finding":"Deletion of the carboxy terminus of AGL (including the glucosidase domain C-terminus and the glycogen-binding domain) in an Agl knockout mouse results in severe glycogen accumulation in liver, skeletal muscle, heart, diaphragm, tongue, and central nervous system, with disruption of contractile units, exercise intolerance, kyphosis, and accelerated respiratory rate, establishing that the glycogen-binding domain is required for normal glycogenolysis in multiple tissues including the CNS.","method":"Knockout mouse generation (carboxy-terminal deletion); biochemical glycogen quantification; histology and electron microscopy; functional testing (exercise tolerance, respiratory rate)","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean knockout with multiple tissue-level biochemical and functional readouts, single lab","pmids":["25092169"],"is_preprint":false},{"year":2000,"finding":"The IVS33+5G>A splice-site mutation in AGL causes aberrant mRNA splicing — specifically skipping of exon 33 and activation of a cryptic splice site in exon 34 — as demonstrated by mRNA sequence analysis of the patient, establishing a mechanism by which an intronic mutation abolishes AGL enzyme activity.","method":"mRNA sequence analysis of patient-derived transcript; family mutational analysis to confirm allele origin","journal":"American journal of medical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct mRNA characterization demonstrating aberrant splicing mechanism, single case, no in vitro reconstitution","pmids":["10925384"],"is_preprint":false},{"year":2023,"finding":"Two novel AGL missense variants (p.Y495C and p.D661Y) reduce glycogen debranching enzyme activity and increase intracellular glycogen content when expressed in transfected cells, while the mutant proteins retain cytoplasmic localization indistinguishable from wild-type AGL, indicating that these mutations impair catalytic function without disrupting subcellular targeting.","method":"Cellular functional validation: transfection of wild-type and mutant AGL constructs, intracellular glycogen content measurement, immunofluorescence for subcellular localization; bioinformatics structural analysis","journal":"International journal of endocrinology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single transfection-based functional assay, no in vitro enzyme reconstitution or structure, single lab, minimal mechanistic depth","pmids":["37287601"],"is_preprint":false}],"current_model":"AGL (glycogen debranching enzyme, GDE) is a bifunctional cytoplasmic enzyme with separable transferase and glucosidase catalytic activities required for glycogen breakdown; its stability is regulated by glycogen binding and by ubiquitination mediated by the E3 ligase Malin, with glycogen depletion promoting partial nuclear relocalization and subsequent proteasomal degradation; in vivo, hepatic AGL governs systemic glucose homeostasis while muscle AGL is required for neuromuscular function; and beyond glycogen metabolism, AGL acts as a tumor suppressor in bladder and lung cancer by restraining HAS2-driven hyaluronic acid synthesis and downstream CD44/RHAMM signaling that otherwise drives tumor proliferation and survival."},"narrative":{"mechanistic_narrative":"AGL encodes the glycogen debranching enzyme (GDE), a bifunctional cytoplasmic enzyme that carries two distinct catalytic activities—a 1,4-alpha-glucan transferase and an amylo-1,6-glucosidase—both required for the final steps of glycogen breakdown [PMID:8954797]. These two activities reside in separable functional domains, since point mutations can selectively abolish glucosidase activity while sparing the transferase [PMID:19834502]. A C-terminal glycogen-binding domain is essential for enzyme function and stability: deletion of this region causes severe multi-tissue glycogen accumulation in vivo [PMID:25092169], and glycogen binding itself stabilizes AGL, with a glycogen-binding-deficient variant showing reduced stability rescued by proteasome inhibition [PMID:17908927]. AGL stability is further governed by the E3 ubiquitin ligase Malin, which physically binds AGL and promotes its ubiquitination, while glycogen depletion drives partial nuclear relocalization and proteasomal degradation [PMID:17908927]. The enzyme has tissue-specific physiological roles directed in part by alternative promoters: hepatic GDE governs systemic blood glucose homeostasis, whereas muscle GDE is required for neuromuscular function, as shown by tissue-targeted gene rescue in Agl knockout mice [PMID:8954797, PMID:29396266]. Loss of AGL function causes glycogen storage disease type III, and structure-guided AAV gene-replacement strategies—including an N-terminally truncated mini-GDE—correct glycogen accumulation and functional deficits across mouse, rat, and human cellular models [PMID:38015640]. Beyond glycogen metabolism, AGL acts as a tumor suppressor: its loss in bladder and lung cancer upregulates HAS2-driven hyaluronic acid synthesis, which signals through CD44 and RHAMM to promote tumor growth and suppress apoptosis [PMID:26490312, PMID:27595989, PMID:29682180], and germline or urothelium-specific Agl knockout mice show increased carcinogen-induced bladder cancer incidence [PMID:30403777].","teleology":[{"year":1996,"claim":"Established that AGL encodes a single multifunctional enzyme with two distinct catalytic activities and tissue-specific isoform expression driven by alternative promoters, defining the molecular basis of glycogen debranching.","evidence":"Gene cloning, structural analysis, and promoter reporter assays in HepG2, C2C12, and CHO cells","pmids":["8954797"],"confidence":"Medium","gaps":["Did not map which residues carry each catalytic activity","Did not establish regulation of isoform switching in vivo"]},{"year":2000,"claim":"Showed that an intronic splice-site mutation abolishes AGL activity through exon skipping and cryptic splice-site activation, defining a splicing mechanism of disease.","evidence":"Patient-derived mRNA sequence analysis with family mutational analysis","pmids":["10925384"],"confidence":"Medium","gaps":["No in vitro reconstitution of the aberrant transcript's protein product","Single case"]},{"year":2007,"claim":"Identified Malin as an E3 ligase partner of AGL and demonstrated that glycogen binding stabilizes AGL while glycogen depletion triggers nuclear relocalization and proteasomal degradation, linking glycogen status to enzyme turnover.","evidence":"Co-IP, ubiquitination assays, proteasome-inhibitor rescue, immunofluorescence in HepG2 cells, and mouse fasting/refeeding experiments","pmids":["17908927"],"confidence":"High","gaps":["Functional consequence of nuclear-localized AGL not defined","Ubiquitination sites on AGL not mapped"]},{"year":2009,"claim":"Demonstrated that the glucosidase and transferase activities are genetically and biochemically separable, since a single missense mutation can abolish glucosidase activity alone.","evidence":"In vitro transferase and glucosidase enzyme assays on patient p.R1147G protein","pmids":["19834502"],"confidence":"Medium","gaps":["No structural model localizing the mutation to the glucosidase active site","Single case, no independent replication"]},{"year":2014,"claim":"Established in vivo that the C-terminal glycogen-binding domain is required for glycogenolysis across multiple tissues including the CNS, connecting glycogen binding to enzyme function organism-wide.","evidence":"C-terminal-deletion Agl knockout mouse with biochemical, histological, EM, and functional assays","pmids":["25092169"],"confidence":"Medium","gaps":["Did not separate loss of binding from loss of catalysis","Single lab"]},{"year":2015,"claim":"Revealed a non-metabolic tumor-suppressive function: AGL loss drives bladder tumor growth via HAS2-mediated hyaluronic acid synthesis.","evidence":"siRNA/shRNA knockdown, 4-methylumbelliferone inhibition, xenograft assays, and patient dataset correlation","pmids":["26490312"],"confidence":"Medium","gaps":["Mechanism by which AGL restrains HAS2 expression not defined","Single lab"]},{"year":2016,"claim":"Placed CD44 and RHAMM downstream of AGL-loss-driven HA synthesis, identifying the receptor arm that promotes growth and suppresses apoptosis.","evidence":"siRNA knockdown of HAS2/CD44/RHAMM, apoptosis Western blots, TUNEL, soft-agar assays in bladder cancer cells","pmids":["27595989"],"confidence":"Medium","gaps":["Downstream signaling effectors of CD44/RHAMM not resolved","Single lab"]},{"year":2017,"claim":"Defined tissue-specific physiological roles by showing hepatic GDE controls systemic glucose homeostasis while muscle GDE controls neuromuscular function.","evidence":"AAV tissue-targeted gene transfer in Agl knockout mice with glucose, muscle-strength, and glycogen readouts plus a GAA negative control","pmids":["29396266"],"confidence":"High","gaps":["CNS contribution to phenotype not separately addressed","Long-term durability of rescue not assessed"]},{"year":2018,"claim":"Extended the AGL→HAS2→HA→RHAMM tumor-suppressive pathway to non-small cell lung cancer, indicating a generalizable mechanism beyond bladder.","evidence":"shRNA/siRNA knockdown, 4MU inhibition, soft-agar and xenograft assays, patient dataset analysis","pmids":["29682180"],"confidence":"Medium","gaps":["Relative contribution of CD44 vs RHAMM in lung not resolved","Single lab"]},{"year":2019,"claim":"Provided direct in vivo genetic proof of AGL tumor suppression in the urothelium and derived an 'Agl Loss' transcriptional signature.","evidence":"Germline and urothelium-specific conditional Agl knockout mice with BBN carcinogen challenge and tumor RNA sequencing","pmids":["30403777"],"confidence":"High","gaps":["Whether HAS2/HA axis drives the in vivo tumor phenotype not directly tested in this model","Signature not validated prospectively"]},{"year":2024,"claim":"Demonstrated that the N-terminal region is dispensable, enabling a mini-GDE gene therapy that corrects glycogen accumulation and functional deficits across mouse, rat, and human cell models of GSDIII.","evidence":"Molecular modeling, truncation mutagenesis, rAAV gene transfer in Agl knockout mice and rats, and a human skeletal muscle cell model","pmids":["38015640"],"confidence":"High","gaps":["Function of the dispensable N-terminal region not defined","Durability and immunogenicity in humans not established"]},{"year":null,"claim":"The molecular mechanism by which AGL loss transcriptionally upregulates HAS2, and how glycogen-metabolic versus tumor-suppressive functions are connected, remain unresolved.","evidence":"Not yet addressed in the available corpus","pmids":[],"confidence":"Low","gaps":["No mechanistic link between AGL enzymatic activity and HAS2 regulation","No structure of full-length AGL","Role of nuclear AGL undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,2]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[1,2]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[1,2,9]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,11]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[1,5,9]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,6,7]}],"complexes":[],"partners":["NHLRC1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P35573","full_name":"Glycogen debranching enzyme","aliases":["Glycogen debrancher"],"length_aa":1532,"mass_kda":174.8,"function":"Multifunctional enzyme acting as 1,4-alpha-D-glucan:1,4-alpha-D-glucan 4-alpha-D-glycosyltransferase and amylo-1,6-glucosidase in glycogen degradation","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P35573/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/AGL","classification":"Not Classified","n_dependent_lines":13,"n_total_lines":1208,"dependency_fraction":0.01076158940397351},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/AGL","total_profiled":1310},"omim":[{"mim_id":"619376","title":"FAUNDES-BANKA SYNDROME; FABAS","url":"https://www.omim.org/entry/619376"},{"mim_id":"619255","title":"BARALLE-MACKEN SYNDROME; BARMACS","url":"https://www.omim.org/entry/619255"},{"mim_id":"615032","title":"INTELLECTUAL DEVELOPMENTAL DISORDER WITH AUTISM AND MACROCEPHALY; IDDAM","url":"https://www.omim.org/entry/615032"},{"mim_id":"613470","title":"ANEMIA, CONGENITAL, NONSPHEROCYTIC HEMOLYTIC, 4; CNSHA4","url":"https://www.omim.org/entry/613470"},{"mim_id":"613019","title":"SUCCINATE DEHYDROGENASE COMPLEX ASSEMBLY FACTOR 2; SDHAF2","url":"https://www.omim.org/entry/613019"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nuclear bodies","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"skeletal muscle","ntpm":241.2},{"tissue":"tongue","ntpm":198.0}],"url":"https://www.proteinatlas.org/search/AGL"},"hgnc":{"alias_symbol":["GDE"],"prev_symbol":[]},"alphafold":{"accession":"P35573","domains":[{"cath_id":"2.60.40.420","chopping":"8-111","consensus_level":"high","plddt":89.6793,"start":8,"end":111},{"cath_id":"-","chopping":"855-1026","consensus_level":"medium","plddt":93.4213,"start":855,"end":1026},{"cath_id":"1.50.10.10","chopping":"1047-1532","consensus_level":"medium","plddt":94.6913,"start":1047,"end":1532}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P35573","model_url":"https://alphafold.ebi.ac.uk/files/AF-P35573-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P35573-F1-predicted_aligned_error_v6.png","plddt_mean":92.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=AGL","jax_strain_url":"https://www.jax.org/strain/search?query=AGL"},"sequence":{"accession":"P35573","fasta_url":"https://rest.uniprot.org/uniprotkb/P35573.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P35573/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P35573"}},"corpus_meta":[{"pmid":"31257871","id":"PMC_31257871","title":"AGL-Score: Algebraic Graph Learning Score for Protein-Ligand Binding Scoring, Ranking, Docking, and Screening.","date":"2019","source":"Journal of chemical information and modeling","url":"https://pubmed.ncbi.nlm.nih.gov/31257871","citation_count":147,"is_preprint":false},{"pmid":"17908927","id":"PMC_17908927","title":"A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease.","date":"2007","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/17908927","citation_count":81,"is_preprint":false},{"pmid":"8954797","id":"PMC_8954797","title":"Human glycogen debranching enzyme gene (AGL): complete structural organization and characterization of the 5' flanking region.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8954797","citation_count":67,"is_preprint":false},{"pmid":"22730124","id":"PMC_22730124","title":"N-glycosylation of Haloferax volcanii flagellins requires known Agl proteins and is essential for biosynthesis of stable flagella.","date":"2012","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/22730124","citation_count":67,"is_preprint":false},{"pmid":"17047887","id":"PMC_17047887","title":"Molecular analysis of the AGL gene: heterogeneity of mutations in patients with glycogen storage disease type III from Germany, Canada, Afghanistan, Iran, and Turkey.","date":"2006","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17047887","citation_count":41,"is_preprint":false},{"pmid":"20648714","id":"PMC_20648714","title":"Molecular analysis of the AGL gene: identification of 25 novel mutations and evidence of genetic heterogeneity in patients with Glycogen Storage Disease Type III.","date":"2010","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20648714","citation_count":38,"is_preprint":false},{"pmid":"29396266","id":"PMC_29396266","title":"Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression.","date":"2017","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29396266","citation_count":31,"is_preprint":false},{"pmid":"16705713","id":"PMC_16705713","title":"Hepatic and neuromuscular forms of glycogenosis type III: nine mutations in AGL.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16705713","citation_count":31,"is_preprint":false},{"pmid":"25092169","id":"PMC_25092169","title":"Glycogen storage disease type III: A novel Agl knockout mouse model.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25092169","citation_count":27,"is_preprint":false},{"pmid":"15364624","id":"PMC_15364624","title":"Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries.","date":"2004","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/15364624","citation_count":27,"is_preprint":false},{"pmid":"11977176","id":"PMC_11977176","title":"Clinical and genetic variability of glycogen storage disease type IIIa: seven novel AGL gene mutations in the Mediterranean area.","date":"2002","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11977176","citation_count":26,"is_preprint":false},{"pmid":"6092692","id":"PMC_6092692","title":"Expression of murine leukemia viruses in B-cell lymphomas of CWD/Agl mice.","date":"1984","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/6092692","citation_count":26,"is_preprint":false},{"pmid":"26490312","id":"PMC_26490312","title":"Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/26490312","citation_count":25,"is_preprint":false},{"pmid":"19834502","id":"PMC_19834502","title":"Molecular features of 23 patients with glycogen storage disease type III in Turkey: a novel mutation p.R1147G associated with isolated glucosidase deficiency, along with 9 AGL mutations.","date":"2009","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19834502","citation_count":25,"is_preprint":false},{"pmid":"27595989","id":"PMC_27595989","title":"CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL).","date":"2016","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27595989","citation_count":24,"is_preprint":false},{"pmid":"12442284","id":"PMC_12442284","title":"Molecular characterisation of GSD III subjects and identification of six novel mutations in AGL.","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12442284","citation_count":24,"is_preprint":false},{"pmid":"29971747","id":"PMC_29971747","title":"Advanced oxidation of antihypertensives losartan and valsartan by photo-electro-Fenton at near-neutral pH using natural organic acids and a dimensional stable anode-gas diffusion electrode (DSA-GDE) system under light emission diode (LED) lighting.","date":"2018","source":"Environmental science and pollution research international","url":"https://pubmed.ncbi.nlm.nih.gov/29971747","citation_count":21,"is_preprint":false},{"pmid":"25462384","id":"PMC_25462384","title":"Glycolytic potential and activity of adenosine monophosphate kinase (AMPK), glycogen phosphorylase (GP) and glycogen debranching enzyme (GDE) in steer carcasses with normal (<5.8) or high (>5.9) 24h pH determined in M. longissimus dorsi.","date":"2014","source":"Meat science","url":"https://pubmed.ncbi.nlm.nih.gov/25462384","citation_count":20,"is_preprint":false},{"pmid":"26984562","id":"PMC_26984562","title":"Spectrum of AGL mutations in Chinese patients with glycogen storage disease type III: identification of 31 novel mutations.","date":"2016","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26984562","citation_count":20,"is_preprint":false},{"pmid":"11924557","id":"PMC_11924557","title":"Mutational and haplotype analysis of AGL in patients with glycogen storage disease type III.","date":"2002","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11924557","citation_count":18,"is_preprint":false},{"pmid":"34259691","id":"PMC_34259691","title":"Integration of aprotic CO2 reduction to oxalate at a Pb catalyst into a GDE flow cell configuration.","date":"2021","source":"Faraday discussions","url":"https://pubmed.ncbi.nlm.nih.gov/34259691","citation_count":17,"is_preprint":false},{"pmid":"24257475","id":"PMC_24257475","title":"A mutation analysis of the AGL gene in Korean patients with glycogen storage disease type III.","date":"2013","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24257475","citation_count":16,"is_preprint":false},{"pmid":"25602008","id":"PMC_25602008","title":"A founder AGL mutation causing glycogen storage disease type IIIa in Inuit identified through whole-exome sequencing: a case series.","date":"2015","source":"CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne","url":"https://pubmed.ncbi.nlm.nih.gov/25602008","citation_count":15,"is_preprint":false},{"pmid":"15542399","id":"PMC_15542399","title":"DNA-based subtyping of glycogen storage disease type III: mutation and haplotype analysis of the AGL gene in Chinese.","date":"2004","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15542399","citation_count":15,"is_preprint":false},{"pmid":"31499309","id":"PMC_31499309","title":"Assessing the efficiency of a pilot-scale GDE/BDD electrochemical system in removing phenol from high salinity waters.","date":"2019","source":"Chemosphere","url":"https://pubmed.ncbi.nlm.nih.gov/31499309","citation_count":15,"is_preprint":false},{"pmid":"23430490","id":"PMC_23430490","title":"Mutation Analysis in Glycogen Storage Disease Type III Patients in the Netherlands: Novel Genotype-Phenotype Relationships and Five Novel Mutations in the AGL Gene.","date":"2012","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/23430490","citation_count":14,"is_preprint":false},{"pmid":"31653959","id":"PMC_31653959","title":"Crystal structure of the catalytic unit of GH 87-type α-1,3-glucanase Agl-KA from Bacillus circulans.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31653959","citation_count":13,"is_preprint":false},{"pmid":"18924225","id":"PMC_18924225","title":"Clinicopathological analysis of the homozygous p.W1327X AGL mutation in glycogen storage disease type 3.","date":"2008","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/18924225","citation_count":13,"is_preprint":false},{"pmid":"19649726","id":"PMC_19649726","title":"SINE indel polymorphism of AGL gene and association with growth and carcass traits in Landrace x Jeju Black pig F(2) population.","date":"2009","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/19649726","citation_count":12,"is_preprint":false},{"pmid":"12955720","id":"PMC_12955720","title":"Mutational analysis of the AGL gene: five novel mutations in GSD III patients.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12955720","citation_count":12,"is_preprint":false},{"pmid":"39190860","id":"PMC_39190860","title":"MutaT7GDE: A Single Chimera for the Targeted, Balanced, Efficient, and Processive Installation of All Possible Transition Mutations In Vivo.","date":"2024","source":"ACS synthetic biology","url":"https://pubmed.ncbi.nlm.nih.gov/39190860","citation_count":11,"is_preprint":false},{"pmid":"38015640","id":"PMC_38015640","title":"A functional mini-GDE transgene corrects impairment in models of glycogen storage disease type III.","date":"2024","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38015640","citation_count":11,"is_preprint":false},{"pmid":"29682180","id":"PMC_29682180","title":"Glycogen debranching enzyme (AGL) is a novel regulator of non-small cell lung cancer growth.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29682180","citation_count":11,"is_preprint":false},{"pmid":"10925384","id":"PMC_10925384","title":"Compound heterozygous patient with glycogen storage disease type III: identification of two novel AGL mutations, a donor splice site mutation of Chinese origin and a 1-bp deletion of Japanese origin.","date":"2000","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10925384","citation_count":11,"is_preprint":false},{"pmid":"34163511","id":"PMC_34163511","title":"Control of the Rhizobia Nitrogen-Fixing Symbiosis by Common Bean MADS-Domain/AGL Transcription Factors.","date":"2021","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/34163511","citation_count":10,"is_preprint":false},{"pmid":"17895567","id":"PMC_17895567","title":"A Japanese patient with cardiomyopathy caused by a novel mutation R285X in the AGL gene.","date":"2007","source":"Circulation journal : official journal of the Japanese Circulation Society","url":"https://pubmed.ncbi.nlm.nih.gov/17895567","citation_count":10,"is_preprint":false},{"pmid":"34726236","id":"PMC_34726236","title":"The yellowhorn AGL transcription factor gene XsAGL22 contributes to ABA biosynthesis and drought tolerance in poplar.","date":"2022","source":"Tree physiology","url":"https://pubmed.ncbi.nlm.nih.gov/34726236","citation_count":8,"is_preprint":false},{"pmid":"19754354","id":"PMC_19754354","title":"Egyptian glycogen storage disease type III - identification of six novel AGL mutations, including a large 1.5 kb deletion and a missense mutation p.L620P with subtype IIId.","date":"2009","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19754354","citation_count":8,"is_preprint":false},{"pmid":"20225301","id":"PMC_20225301","title":"Insertion of multiple alpha-amino gamma-lactam (Agl) residues into a peptide sequence by solid-phase synthesis on synphase lanterns.","date":"2010","source":"Biopolymers","url":"https://pubmed.ncbi.nlm.nih.gov/20225301","citation_count":8,"is_preprint":false},{"pmid":"27515074","id":"PMC_27515074","title":"Preparation of Colloidal Gold Particles and Conjugation to Protein A/G/L, IgG, F(ab')2, and Streptavidin.","date":"2016","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/27515074","citation_count":7,"is_preprint":false},{"pmid":"22035446","id":"PMC_22035446","title":"A c.3216_3217delGA mutation in AGL gene in Tunisian patients with a glycogen storage disease type III: evidence of a founder effect.","date":"2011","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22035446","citation_count":6,"is_preprint":false},{"pmid":"9257806","id":"PMC_9257806","title":"alpha-Galactosylceramide (AGL-517) treatment protects mice from lethal irradiation.","date":"1997","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/9257806","citation_count":6,"is_preprint":false},{"pmid":"17905541","id":"PMC_17905541","title":"Characterization of the equine glycogen debranching enzyme gene (AGL): Genomic and cDNA structure, localization, polymorphism and expression.","date":"2007","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/17905541","citation_count":5,"is_preprint":false},{"pmid":"40641508","id":"PMC_40641508","title":"GDE Stability in CO2 Electroreduction to Formate: The Role of Ionomer Type and Loading.","date":"2025","source":"ACS catalysis","url":"https://pubmed.ncbi.nlm.nih.gov/40641508","citation_count":5,"is_preprint":false},{"pmid":"23688858","id":"PMC_23688858","title":"Liver cirrhosis treated by living donor liver transplantation in a patient with AGL mutation c.2607-2610delATTC and c.1672dupA.","date":"2013","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23688858","citation_count":5,"is_preprint":false},{"pmid":"30403777","id":"PMC_30403777","title":"Elucidating the role of Agl in bladder carcinogenesis by generation and characterization of genetically engineered mice.","date":"2019","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30403777","citation_count":4,"is_preprint":false},{"pmid":"26885414","id":"PMC_26885414","title":"A Novel Nonsense Mutation of the AGL Gene in a Romanian Patient with Glycogen Storage Disease Type IIIa.","date":"2016","source":"Case reports in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26885414","citation_count":3,"is_preprint":false},{"pmid":"37287601","id":"PMC_37287601","title":"Clinical and Functional Characterization of Novel AGL Variants in Two Families with Glycogen Storage Disease Type III.","date":"2023","source":"International journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/37287601","citation_count":2,"is_preprint":false},{"pmid":"38592052","id":"PMC_38592052","title":"Identification of Novel and Recurrent Variants in BTD, GBE1, AGL and ASL Genes in Families with Metabolic Disorders in Saudi Arabia.","date":"2024","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38592052","citation_count":2,"is_preprint":false},{"pmid":"35578201","id":"PMC_35578201","title":"The biallelic novel pathogenic variants in AGL gene in a chinese patient with glycogen storage disease type III.","date":"2022","source":"BMC pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/35578201","citation_count":2,"is_preprint":false},{"pmid":"24495762","id":"PMC_24495762","title":"[AGL gene analysis of a pedigree with glycogen storage disease type III and identification of a novel mutation].","date":"2013","source":"Zhonghua er ke za zhi = Chinese journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/24495762","citation_count":2,"is_preprint":false},{"pmid":"33329302","id":"PMC_33329302","title":"The Novel Compound Heterozygous Mutations in the AGL Gene in a Chinese Family With Adult Late-Onset Glycogen Storage Disease Type IIIa.","date":"2020","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33329302","citation_count":2,"is_preprint":false},{"pmid":"29310060","id":"PMC_29310060","title":"Generation of a GDE heterozygous mutation human embryonic stem cell line WAe001-A-14 by CRISPR/Cas9 editing.","date":"2017","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/29310060","citation_count":1,"is_preprint":false},{"pmid":"38822779","id":"PMC_38822779","title":"Design and Application of a Gas Diffusion Electrode (GDE) Cell for Operando and In Situ Studies.","date":"2024","source":"Chimia","url":"https://pubmed.ncbi.nlm.nih.gov/38822779","citation_count":1,"is_preprint":false},{"pmid":"31028654","id":"PMC_31028654","title":"Intron retention is among six unreported AGL mutations identified in Malaysian GSD III patients.","date":"2019","source":"Genes & genomics","url":"https://pubmed.ncbi.nlm.nih.gov/31028654","citation_count":1,"is_preprint":false},{"pmid":"26252094","id":"PMC_26252094","title":"[Analysis of clinical features and AGL gene mutations in a family with glycogen storage disease type IIIa].","date":"2015","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26252094","citation_count":1,"is_preprint":false},{"pmid":"41054315","id":"PMC_41054315","title":"The Common Bean miR172c microRNA, a Relevant Regulator of the N-Fixing Symbiosis, Is Activated by SPL and AGL/MADS-Domain Transcription Factors.","date":"2025","source":"Physiologia plantarum","url":"https://pubmed.ncbi.nlm.nih.gov/41054315","citation_count":1,"is_preprint":false},{"pmid":"37035733","id":"PMC_37035733","title":"Novel AGL variants in a patient with glycogen storage disease type IIIb and pulmonary hypertension caused by pulmonary veno-occlusive disease: A case report.","date":"2023","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37035733","citation_count":1,"is_preprint":false},{"pmid":"38825558","id":"PMC_38825558","title":"Domain structure and function of α-1,3-glucanase Agl-EK14 from the gram-negative bacterium Flavobacterium sp. EK-14.","date":"2024","source":"Journal of bioscience and bioengineering","url":"https://pubmed.ncbi.nlm.nih.gov/38825558","citation_count":0,"is_preprint":false},{"pmid":"34729746","id":"PMC_34729746","title":"[Analysis of two cases of glycogen storage disease type III due to compound heterozygous variants of AGL gene].","date":"2021","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34729746","citation_count":0,"is_preprint":false},{"pmid":"41389110","id":"PMC_41389110","title":"Identification of a novel nonsense mutation in the AGL gene in glycogen storage disease type IIIa: first genetically confirmed case report from Morocco.","date":"2025","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/41389110","citation_count":0,"is_preprint":false},{"pmid":"28777846","id":"PMC_28777846","title":"[Identification of a novel mutation of AGL gene in two siblings affected with glycogen storage disease type IIIa].","date":"2017","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28777846","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.27.691070","title":"Evaluating drone-mounted thermal infrared sensors for macropod monitoring in Tasmania","date":"2025-12-01","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.27.691070","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.10.664142","title":"Newly-identified lentil genotypes adapted to Mediterranean agro-ecosystems","date":"2025-07-15","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.10.664142","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.02.19.25322160","title":"T cell-intrinsic lymphoproliferation as a key driver of intestinal autoimmunity in acquired generalized lipodystrophy","date":"2025-02-24","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.19.25322160","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":32620,"output_tokens":3492,"usd":0.07512,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11353,"output_tokens":3552,"usd":0.072782,"stage2_stop_reason":"end_turn"},"total_usd":0.147902,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"The E3 ubiquitin ligase Malin physically interacts with AGL and promotes its ubiquitination. The disease-causing G1448R variant of AGL is unable to bind glycogen, shows decreased protein stability rescued by proteasomal inhibition, and forms aggresomes upon proteasome impairment, indicating that glycogen binding is required for AGL stability. Stimulation with cAMP-elevating agents increases Malin levels and Malin/AGL complex formation. After glycogen depletion, AGL redistributes from cytoplasm to partial nuclear localization in ~90% of transfected HepG2 cells. Refeeding mice after an overnight fast reduces hepatic AGL levels by 48%, consistent with ubiquitin-mediated degradation.\",\n      \"method\": \"Co-immunoprecipitation, transfection studies in HepG2 cells, proteasome inhibitor rescue, immunofluorescence localization, in vivo mouse refeeding/fasting experiments, ubiquitination assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP for Malin-AGL interaction, multiple orthogonal methods (ubiquitination assay, proteasome inhibitor rescue, subcellular localization, in vivo mouse experiments), single lab but comprehensive mechanistic dissection\",\n      \"pmids\": [\"17908927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The human AGL gene encodes a multifunctional enzyme with two distinct catalytic activities: 1,4-alpha-D-glucan:1,4-alpha-D-glucan 4-alpha-D-glycosyltransferase (transferase) and amylo-1,6-glucosidase (glucosidase), both required for glycogen debranching. The gene contains at least two promoter regions conferring tissue-specific isoform expression: promoter 1 (for isoform 1) is active in liver, muscle, and ovary cells, while promoter 2 (for muscle-specific isoforms 2–4) is active only in muscle, as demonstrated by reporter assays.\",\n      \"method\": \"Gene cloning and structural analysis, reporter (promoter) assays in HepG2, C2C12, and CHO cells, mRNA isoform characterization\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct reporter assays establishing promoter tissue-specificity, single lab, two orthogonal approaches (structural analysis + functional assays)\",\n      \"pmids\": [\"8954797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"A missense mutation p.R1147G in AGL selectively abolishes glucosidase activity while maintaining transferase activity in vitro, demonstrating that these two catalytic activities reside in separable functional domains and that isolated glucosidase deficiency can result from a single missense mutation.\",\n      \"method\": \"In vitro enzyme activity assays (transferase and glucosidase) on mutant protein from a patient homozygous for p.R1147G, confirmed by clinical diagnosis of isolated glucosidase deficiency\",\n      \"journal\": \"Journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct in vitro biochemical assay demonstrating dissociable catalytic activities, single case/lab, no independent replication reported\",\n      \"pmids\": [\"19834502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Loss of AGL in bladder cancer cells drives tumor growth through upregulation of hyaluronic acid synthase 2 (HAS2)-mediated hyaluronic acid (HA) synthesis. siRNA-mediated depletion of HAS2 or pharmacological inhibition of HA synthesis (4-methylumbelliferone) abrogated anchorage-dependent and independent growth, as well as xenograft growth, of AGL-low bladder cancer cells. AGL and HAS2 mRNA expression are inversely correlated in patient datasets.\",\n      \"method\": \"shRNA/siRNA knockdown, xenograft tumor growth assays, pharmacological inhibition (4MU), transcriptional profiling, clinicopathologic dataset analysis\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal loss-of-function approaches (siRNA, pharmacological inhibitor, xenograft), single lab\",\n      \"pmids\": [\"26490312\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In bladder cancer cells with low AGL expression, HA synthesized by HAS2 signals through receptors CD44 and RHAMM to promote anchorage-dependent and independent growth and suppress apoptosis. Loss of CD44 or RHAMM individually induces apoptosis (evidenced by cleaved Cas3, Cas9, PARP, and TUNEL staining) in AGL-low bladder cancer cell lines, placing CD44 and RHAMM downstream of AGL loss → HAS2 → HA in this tumor growth pathway.\",\n      \"method\": \"siRNA knockdown of HAS2, CD44, RHAMM; Western blot for apoptosis markers; TUNEL assay; proliferation and soft-agar assays; clinicopathologic analysis of patient datasets\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal knockdown experiments with defined apoptosis and growth readouts, single lab, replicates and extends prior AGL/HAS2 findings\",\n      \"pmids\": [\"27595989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"AAV-mediated restoration of GDE (AGL) expression in liver directly impacts blood glucose levels, while restoration in muscle rescues functional deficits (muscle weakness) without affecting glucose metabolism, establishing tissue-specific roles for GDE: hepatic GDE governs systemic glucose homeostasis and muscle GDE is required for neuromuscular function. Overexpression of the lysosomal enzyme GAA reduced liver glycogen but failed to reverse the overall GSDIII disease phenotype.\",\n      \"method\": \"AAV vector-mediated gene transfer in Agl knockout mice; tissue-specific expression constructs; functional assays (blood glucose, muscle strength); histological and biochemical quantification of glycogen\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean in vivo rescue with tissue-targeted vectors plus negative control (GAA), multiple functional and biochemical readouts, proof-of-concept replicated across liver and muscle compartments\",\n      \"pmids\": [\"29396266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Loss of AGL in non-small cell lung cancer (NSCLC) cells promotes anchorage-independent and xenograft tumor growth through upregulation of HAS2-driven HA synthesis, with HA signaling through RHAMM being critical for growth of AGL-low NSCLC cells, extending the AGL → HAS2 → HA → RHAMM tumor-suppressive pathway to a second cancer type.\",\n      \"method\": \"shRNA knockdown of AGL; siRNA knockdown of HAS2 and RHAMM; pharmacological inhibition of HA synthesis (4MU); soft-agar and xenograft growth assays; patient dataset analysis\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal loss-of-function approaches in a second tumor type, single lab, consistent with prior bladder cancer findings\",\n      \"pmids\": [\"29682180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Germline Agl knockout mice (with urothelium-specific conditional knockout also generated) show increased bladder cancer incidence upon carcinogen (BBN) treatment compared to wild-type, establishing a direct in vivo tumor-suppressive role for AGL in the urothelium. RNA sequencing of tumors from Agl−/− mice identified 19 differentially expressed genes, enabling derivation of an 'Agl Loss' gene signature.\",\n      \"method\": \"Germline Agl knockout mouse generation; urothelium-specific conditional knockout (Uroplakin II-Cre); BBN carcinogen treatment; histopathological assessment of bladder cancer incidence; RNA sequencing\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo germline and conditional knockout with carcinogen challenge, two independent mouse models converging on same phenotype, single lab\",\n      \"pmids\": [\"30403777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"An N-terminal-truncated AGL mutant (ΔNter2-GDE) retains full enzymatic efficacy in vivo, demonstrating that the N-terminal region of GDE is dispensable for glycogen debranching function. rAAV vectors expressing this mini-GDE significantly reduced glycogen accumulation in heart and muscle of Agl−/− mice and corrected histological and functional deficits (including normalization of muscle strength) in both mouse and rat Agl knockout models, and also corrected glycogen accumulation in a human skeletal muscle cellular model of GSDIII.\",\n      \"method\": \"Molecular modeling and truncation mutagenesis; rAAV-mediated in vivo gene transfer in Agl−/− mice and rats; glycogen quantification; histological analysis; muscle strength testing; in vitro human skeletal muscle cell model correction\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structure-guided mutagenesis combined with in vivo and in vitro functional rescue in multiple models (mouse, rat, human cells), multiple orthogonal readouts\",\n      \"pmids\": [\"38015640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Deletion of the carboxy terminus of AGL (including the glucosidase domain C-terminus and the glycogen-binding domain) in an Agl knockout mouse results in severe glycogen accumulation in liver, skeletal muscle, heart, diaphragm, tongue, and central nervous system, with disruption of contractile units, exercise intolerance, kyphosis, and accelerated respiratory rate, establishing that the glycogen-binding domain is required for normal glycogenolysis in multiple tissues including the CNS.\",\n      \"method\": \"Knockout mouse generation (carboxy-terminal deletion); biochemical glycogen quantification; histology and electron microscopy; functional testing (exercise tolerance, respiratory rate)\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean knockout with multiple tissue-level biochemical and functional readouts, single lab\",\n      \"pmids\": [\"25092169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The IVS33+5G>A splice-site mutation in AGL causes aberrant mRNA splicing — specifically skipping of exon 33 and activation of a cryptic splice site in exon 34 — as demonstrated by mRNA sequence analysis of the patient, establishing a mechanism by which an intronic mutation abolishes AGL enzyme activity.\",\n      \"method\": \"mRNA sequence analysis of patient-derived transcript; family mutational analysis to confirm allele origin\",\n      \"journal\": \"American journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct mRNA characterization demonstrating aberrant splicing mechanism, single case, no in vitro reconstitution\",\n      \"pmids\": [\"10925384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Two novel AGL missense variants (p.Y495C and p.D661Y) reduce glycogen debranching enzyme activity and increase intracellular glycogen content when expressed in transfected cells, while the mutant proteins retain cytoplasmic localization indistinguishable from wild-type AGL, indicating that these mutations impair catalytic function without disrupting subcellular targeting.\",\n      \"method\": \"Cellular functional validation: transfection of wild-type and mutant AGL constructs, intracellular glycogen content measurement, immunofluorescence for subcellular localization; bioinformatics structural analysis\",\n      \"journal\": \"International journal of endocrinology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single transfection-based functional assay, no in vitro enzyme reconstitution or structure, single lab, minimal mechanistic depth\",\n      \"pmids\": [\"37287601\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"AGL (glycogen debranching enzyme, GDE) is a bifunctional cytoplasmic enzyme with separable transferase and glucosidase catalytic activities required for glycogen breakdown; its stability is regulated by glycogen binding and by ubiquitination mediated by the E3 ligase Malin, with glycogen depletion promoting partial nuclear relocalization and subsequent proteasomal degradation; in vivo, hepatic AGL governs systemic glucose homeostasis while muscle AGL is required for neuromuscular function; and beyond glycogen metabolism, AGL acts as a tumor suppressor in bladder and lung cancer by restraining HAS2-driven hyaluronic acid synthesis and downstream CD44/RHAMM signaling that otherwise drives tumor proliferation and survival.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"AGL encodes the glycogen debranching enzyme (GDE), a bifunctional cytoplasmic enzyme that carries two distinct catalytic activities—a 1,4-alpha-glucan transferase and an amylo-1,6-glucosidase—both required for the final steps of glycogen breakdown [#1]. These two activities reside in separable functional domains, since point mutations can selectively abolish glucosidase activity while sparing the transferase [#2]. A C-terminal glycogen-binding domain is essential for enzyme function and stability: deletion of this region causes severe multi-tissue glycogen accumulation in vivo [#9], and glycogen binding itself stabilizes AGL, with a glycogen-binding-deficient variant showing reduced stability rescued by proteasome inhibition [#0]. AGL stability is further governed by the E3 ubiquitin ligase Malin, which physically binds AGL and promotes its ubiquitination, while glycogen depletion drives partial nuclear relocalization and proteasomal degradation [#0]. The enzyme has tissue-specific physiological roles directed in part by alternative promoters: hepatic GDE governs systemic blood glucose homeostasis, whereas muscle GDE is required for neuromuscular function, as shown by tissue-targeted gene rescue in Agl knockout mice [#1, #5]. Loss of AGL function causes glycogen storage disease type III, and structure-guided AAV gene-replacement strategies—including an N-terminally truncated mini-GDE—correct glycogen accumulation and functional deficits across mouse, rat, and human cellular models [#8]. Beyond glycogen metabolism, AGL acts as a tumor suppressor: its loss in bladder and lung cancer upregulates HAS2-driven hyaluronic acid synthesis, which signals through CD44 and RHAMM to promote tumor growth and suppress apoptosis [#3, #4, #6], and germline or urothelium-specific Agl knockout mice show increased carcinogen-induced bladder cancer incidence [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established that AGL encodes a single multifunctional enzyme with two distinct catalytic activities and tissue-specific isoform expression driven by alternative promoters, defining the molecular basis of glycogen debranching.\",\n      \"evidence\": \"Gene cloning, structural analysis, and promoter reporter assays in HepG2, C2C12, and CHO cells\",\n      \"pmids\": [\"8954797\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not map which residues carry each catalytic activity\", \"Did not establish regulation of isoform switching in vivo\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showed that an intronic splice-site mutation abolishes AGL activity through exon skipping and cryptic splice-site activation, defining a splicing mechanism of disease.\",\n      \"evidence\": \"Patient-derived mRNA sequence analysis with family mutational analysis\",\n      \"pmids\": [\"10925384\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vitro reconstitution of the aberrant transcript's protein product\", \"Single case\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified Malin as an E3 ligase partner of AGL and demonstrated that glycogen binding stabilizes AGL while glycogen depletion triggers nuclear relocalization and proteasomal degradation, linking glycogen status to enzyme turnover.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, proteasome-inhibitor rescue, immunofluorescence in HepG2 cells, and mouse fasting/refeeding experiments\",\n      \"pmids\": [\"17908927\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of nuclear-localized AGL not defined\", \"Ubiquitination sites on AGL not mapped\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrated that the glucosidase and transferase activities are genetically and biochemically separable, since a single missense mutation can abolish glucosidase activity alone.\",\n      \"evidence\": \"In vitro transferase and glucosidase enzyme assays on patient p.R1147G protein\",\n      \"pmids\": [\"19834502\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model localizing the mutation to the glucosidase active site\", \"Single case, no independent replication\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established in vivo that the C-terminal glycogen-binding domain is required for glycogenolysis across multiple tissues including the CNS, connecting glycogen binding to enzyme function organism-wide.\",\n      \"evidence\": \"C-terminal-deletion Agl knockout mouse with biochemical, histological, EM, and functional assays\",\n      \"pmids\": [\"25092169\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not separate loss of binding from loss of catalysis\", \"Single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Revealed a non-metabolic tumor-suppressive function: AGL loss drives bladder tumor growth via HAS2-mediated hyaluronic acid synthesis.\",\n      \"evidence\": \"siRNA/shRNA knockdown, 4-methylumbelliferone inhibition, xenograft assays, and patient dataset correlation\",\n      \"pmids\": [\"26490312\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which AGL restrains HAS2 expression not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Placed CD44 and RHAMM downstream of AGL-loss-driven HA synthesis, identifying the receptor arm that promotes growth and suppresses apoptosis.\",\n      \"evidence\": \"siRNA knockdown of HAS2/CD44/RHAMM, apoptosis Western blots, TUNEL, soft-agar assays in bladder cancer cells\",\n      \"pmids\": [\"27595989\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream signaling effectors of CD44/RHAMM not resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined tissue-specific physiological roles by showing hepatic GDE controls systemic glucose homeostasis while muscle GDE controls neuromuscular function.\",\n      \"evidence\": \"AAV tissue-targeted gene transfer in Agl knockout mice with glucose, muscle-strength, and glycogen readouts plus a GAA negative control\",\n      \"pmids\": [\"29396266\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CNS contribution to phenotype not separately addressed\", \"Long-term durability of rescue not assessed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extended the AGL→HAS2→HA→RHAMM tumor-suppressive pathway to non-small cell lung cancer, indicating a generalizable mechanism beyond bladder.\",\n      \"evidence\": \"shRNA/siRNA knockdown, 4MU inhibition, soft-agar and xenograft assays, patient dataset analysis\",\n      \"pmids\": [\"29682180\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of CD44 vs RHAMM in lung not resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Provided direct in vivo genetic proof of AGL tumor suppression in the urothelium and derived an 'Agl Loss' transcriptional signature.\",\n      \"evidence\": \"Germline and urothelium-specific conditional Agl knockout mice with BBN carcinogen challenge and tumor RNA sequencing\",\n      \"pmids\": [\"30403777\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HAS2/HA axis drives the in vivo tumor phenotype not directly tested in this model\", \"Signature not validated prospectively\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated that the N-terminal region is dispensable, enabling a mini-GDE gene therapy that corrects glycogen accumulation and functional deficits across mouse, rat, and human cell models of GSDIII.\",\n      \"evidence\": \"Molecular modeling, truncation mutagenesis, rAAV gene transfer in Agl knockout mice and rats, and a human skeletal muscle cell model\",\n      \"pmids\": [\"38015640\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Function of the dispensable N-terminal region not defined\", \"Durability and immunogenicity in humans not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular mechanism by which AGL loss transcriptionally upregulates HAS2, and how glycogen-metabolic versus tumor-suppressive functions are connected, remain unresolved.\",\n      \"evidence\": \"Not yet addressed in the available corpus\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No mechanistic link between AGL enzymatic activity and HAS2 regulation\", \"No structure of full-length AGL\", \"Role of nuclear AGL undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [1, 2, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 11]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [1, 5, 9]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 6, 7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"NHLRC1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}